Revenue by source
Eliquis$14.44BOpdivo$10.05BRevlimid$2.95BOrencia$3.71BMature Products And All Other$0.00Sprycel$493.00MYervoy$2.90BPomalyst/Imnovid$2.73BBaraclude$0.00Abilify$0.00Sustiva Franchise$0.00Reyataz$0.00Reblozyl$2.33BAbraxane$368.00MHepatitis C Portfolio$0.00Other Growth Brands$1.92BOpdualag$1.19BBreyanzi$1.36BErbitux$0.00Zeposia$577.00MCamzyos$1.07BAbecma$427.00MOther Legacy Brands$798.00MEmpliciti$0.00Sotyktu$291.00MKrazati$205.00MDiabetes alliance$0.00Opdivo Ovantig$238.00MCobenfy$155.00M
| Segment | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Eliquis | - | $2.00M | $146.00M | $774.00M | $1.86B | $3.34B | $4.87B | $6.44B | $7.93B | $9.17B | $10.76B | $11.79B | $12.21B | $13.33B | $14.44B |
| Opdivo | - | - | - | $6.00M | $942.00M | $3.77B | $4.95B | $6.74B | $7.20B | $6.99B | $7.52B | $8.25B | $9.01B | $9.30B | $10.05B |
| Revlimid | - | - | - | - | - | - | - | - | $1.30B | $12.11B | $12.82B | $9.98B | $6.10B | $5.77B | $2.95B |
| Orencia | - | $1.18B | $1.44B | $1.65B | $1.89B | $2.27B | $2.48B | $2.71B | $2.98B | $3.16B | $3.31B | $3.46B | $3.60B | $3.68B | $3.71B |
| Mature Products And All Other | $2.95B | $2.76B | $2.77B | $3.11B | $2.57B | $2.14B | $2.11B | $1.63B | $1.67B | $1.32B | $1.90B | $1.75B | - | - | - |
| Sprycel | - | $1.02B | $1.28B | $1.49B | $1.62B | $1.82B | $2.01B | $2.00B | $2.11B | $2.14B | $2.12B | $2.17B | $1.93B | $1.29B | $493.00M |
| Yervoy | - | $706.00M | $960.00M | $1.31B | $1.13B | $1.05B | $1.24B | $1.33B | $1.49B | $1.68B | $2.03B | $2.13B | $2.24B | $2.53B | $2.90B |
| Pomalyst/Imnovid | - | - | - | - | - | - | - | - | $322.00M | $3.07B | $3.33B | $3.50B | $3.44B | $3.55B | $2.73B |
| Baraclude | - | $1.39B | $1.53B | $1.44B | $1.31B | $1.19B | $1.05B | $744.00M | $555.00M | $447.00M | - | - | - | - | - |
| Abilify | - | $2.83B | $2.29B | $2.02B | $746.00M | $128.00M | - | - | - | - | - | - | - | - | - |
| Sustiva Franchise | - | $1.53B | $1.61B | $1.44B | $1.25B | $1.07B | $729.00M | $283.00M | - | - | - | - | - | - | - |
| Reyataz | - | $1.52B | $1.55B | $1.36B | $1.14B | $912.00M | $698.00M | $427.00M | - | - | - | - | - | - | - |
| Reblozyl | - | - | - | - | - | - | - | - | - | $274.00M | $551.00M | $717.00M | $1.01B | $1.77B | $2.33B |
| Abraxane | - | - | - | - | - | - | - | - | $166.00M | $1.25B | $1.18B | $811.00M | $1.00B | $875.00M | $368.00M |
| Hepatitis C Portfolio | - | - | - | $256.00M | $1.60B | $1.58B | $406.00M | $17.00M | - | - | - | - | - | - | - |
| Other Growth Brands | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.61B | $1.92B |
| Opdualag | - | - | - | - | - | - | - | - | - | - | - | $252.00M | $627.00M | $928.00M | $1.19B |
| Breyanzi | - | - | - | - | - | - | - | - | - | - | $87.00M | $182.00M | $364.00M | $747.00M | $1.36B |
| Erbitux | - | $702.00M | $696.00M | $723.00M | $501.00M | - | - | - | - | - | - | - | - | - | - |
| Zeposia | - | - | - | - | - | - | - | - | - | $12.00M | $134.00M | $250.00M | $434.00M | $566.00M | $577.00M |
| Camzyos | - | - | - | - | - | - | - | - | - | - | - | $24.00M | $231.00M | $602.00M | $1.07B |
| Abecma | - | - | - | - | - | - | - | - | - | - | $164.00M | $388.00M | $472.00M | $406.00M | $427.00M |
| Other Legacy Brands | - | - | - | - | - | - | - | - | - | - | - | - | - | $925.00M | $798.00M |
| Empliciti | - | - | - | - | $3.00M | $150.00M | $231.00M | $247.00M | $357.00M | $381.00M | - | - | - | - | - |
| Sotyktu | - | - | - | - | - | - | - | - | - | - | - | $8.00M | $170.00M | $246.00M | $291.00M |
| Krazati | - | - | - | - | - | - | - | - | - | - | - | - | - | $126.00M | $205.00M |
| Diabetes alliance | - | - | - | $295.00M | - | - | - | - | - | - | - | - | - | - | - |
| Opdivo Ovantig | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $238.00M |
| Cobenfy | - | - | - | - | - | - | - | - | - | - | - | - | - | $10.00M | $155.00M |
Revenue by country
UNITED STATES$33.28BEurope$0.00Rest Of World$0.00Other Region$1.09BEmerging Markets$0.00Japan, Asia Pacific and Canada$0.00Latin America, Middle East and Africa$0.00Segment, Other$0.00
| Segment | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| UNITED STATES | - | $13.85B | $10.38B | $8.32B | $7.72B | $8.19B | $10.72B | $11.36B | $12.59B | $15.34B | $26.58B | $29.21B | $31.83B | $31.56B | $34.11B | $33.28B |
| Europe | $3.45B | $3.67B | $3.71B | $3.93B | $3.59B | $3.49B | $4.22B | $4.99B | $5.66B | $6.27B | $9.85B | $10.69B | $13.50B | - | - | - |
| Rest Of World | - | - | $3.20B | $3.30B | $3.46B | $4.14B | $3.96B | $3.88B | $3.73B | $4.01B | $5.46B | $5.63B | - | $12.75B | $13.20B | - |
| Other Region | - | $89.00M | $327.00M | $842.00M | $1.11B | $739.00M | $528.00M | $553.00M | $584.00M | $524.00M | $631.00M | $852.00M | $834.00M | $699.00M | $996.00M | $1.09B |
| Emerging Markets | $804.00M | $887.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Japan, Asia Pacific and Canada | $1.65B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Latin America, Middle East and Africa | $856.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Segment, Other | $112.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |